Moderna (NASDAQ: MRNA) 30-day option implied volatility is at 73; compared to its 52-week range of 54 to 90. Call put ratio 14 calls to 1 put with a focus on May 22 weekly 52, 55 and 57 calls into Moderna's experimental mRNA-based flu vaccine will be reviewed by an FDA advisory panel on June 18 ahead of an August 5 approval decision.